Back to McKinsey Chart of the Day

Pandemic delays development of innovative cell and gene therapies

Work on innovative treatments for severe diseases (such as cancer) has slowed to prevent clinical-trial participants from being exposed to COVID-19. Almost two-thirds of the companies we surveyed expect their development programs to be delayed by more than three months.

We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at:

To read the article, see “COVID-19 and cell and gene therapy: How to keep innovation on track,” August 18, 2020.